PLGA 基纳米粒子:生物医学应用概述。
PLGA-based nanoparticles: an overview of biomedical applications.
机构信息
Université Catholique de Louvain, Louvain Drug Research Institute, Pharmaceutics and Drug Delivery, Avenue Mounier, B1 73.12, 1200 Brussels, Belgium.
出版信息
J Control Release. 2012 Jul 20;161(2):505-22. doi: 10.1016/j.jconrel.2012.01.043. Epub 2012 Feb 4.
Poly(lactic-co-glycolic acid) (PLGA) is one of the most successfully developed biodegradable polymers. Among the different polymers developed to formulate polymeric nanoparticles, PLGA has attracted considerable attention due to its attractive properties: (i) biodegradability and biocompatibility, (ii) FDA and European Medicine Agency approval in drug delivery systems for parenteral administration, (iii) well described formulations and methods of production adapted to various types of drugs e.g. hydrophilic or hydrophobic small molecules or macromolecules, (iv) protection of drug from degradation, (v) possibility of sustained release, (vi) possibility to modify surface properties to provide stealthness and/or better interaction with biological materials and (vii) possibility to target nanoparticles to specific organs or cells. This review presents why PLGA has been chosen to design nanoparticles as drug delivery systems in various biomedical applications such as vaccination, cancer, inflammation and other diseases. This review focuses on the understanding of specific characteristics exploited by PLGA-based nanoparticles to target a specific organ or tissue or specific cells.
聚(乳酸-共-乙醇酸)(PLGA)是最成功开发的可生物降解聚合物之一。在为制备聚合物纳米粒而开发的不同聚合物中,由于其具有以下吸引人的特性,PLGA 引起了相当大的关注:(i)可生物降解性和生物相容性;(ii)美国食品药品监督管理局和欧洲药品管理局批准将其用于可注射的药物输送系统;(iii)有良好描述的制剂和生产方法,适用于各种类型的药物,例如亲水性或疏水性小分子或大分子;(iv)保护药物免受降解;(v)可以实现缓释;(vi)可以修饰表面性质以提供隐形性和/或更好地与生物材料相互作用;(vii)可以将纳米粒靶向特定器官或细胞。本文综述了为什么选择 PLGA 来设计用于各种生物医学应用(例如疫苗接种、癌症、炎症和其他疾病)的纳米粒作为药物输送系统。本文重点介绍了理解基于 PLGA 的纳米粒靶向特定器官或组织或特定细胞所利用的特定特性。